Navigation Links
Cervarix Proves Effective Against HPV for Over 6 Years
Date:12/3/2009

Vaccine protected volunteers from virus linked to cervical cancer

WEDNESDAY, Dec. 2 (HealthDay News) -- The human papillomavirus (HPV) vaccine Cervarix protects women from infection for longer than six years, new research has found.

The vaccine guards against the two types of HPV (HPV-16 and HPV-18) most commonly associated with cervical cancer.

The study looked at nearly 800 women, aged 15 to 25, with a normal cervical profile and no evidence of HPV infection at the start of the trial. There were 393 women who received the Cervarix vaccine and 383 who received an inactive placebo. Every six months for 6.4 years, the women were tested for HPV DNA.

The researchers found that vaccine efficacy against 12-month persistent infection with HPV-16/18 remained 100 percent during the study period. Vaccine efficacy against incident infection with HPV-16/18 was 95 percent. Antibody concentrations against HPV-16/18 in vaccinated women remained at least several-fold higher than would be found after natural HPV infection, the study authors noted.

Cervarix also protected women against incident infection with HPV-31 and HPV-45, which "are among the types most frequently associated with cervical cancer after HPV-16 and HPV-18, and are responsible for 10 percent of all cervical cancer cases," wrote Dr. Cosette Wheeler, of the Health Sciences Center at the University of New Mexico, and colleagues.

The study was released online Dec. 2 in advance of publication in an upcoming print issue of The Lancet.

"Although further assessment is necessary to confirm long-term vaccine effects, in view of the data from our study, we expect protection to continue for many more years," the researchers concluded.

Cervarix, from GlaxoSmithKline, received U.S. Food and Drug Administration approval in October.

More information

The U.S. National Cancer Institute has more about HPV vaccines.



-- Robert Preidt



SOURCE: The Lancet, news release, Dec. 2, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. Nasal Anthrax Vaccine Proves Effective in Animal Study
3. FDA Approves New Roche West Nile Virus Blood Screening Test
4. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
5. Exercise and yoga improves quality of life in women with early-stage breast cancer
6. Toddler Study Proves Humans Outsmart Apes
7. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
8. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
9. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
10. FDA Approves SOMA(R) (carisoprodol) 250 mg
11. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... miniature, folded, pharmaceutical inserts and outserts. As a means of expanding capabilities ... addition will enable Flottman to individually code professional inserts (PIs) and patient package ...
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
(Date:12/9/2016)... ... 09, 2016 , ... The Holy Name Medical Center Foundation ... on December 3rd, to benefit Holy Name Medical Center's programs and services. More ... over $1 million - the largest event in the Center's history, both in ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)... 2016 KEY FINDINGS The global ... 2017-2023. Various reasons for growth of the medical lifting ... of chronic diseases, high recovery cost of injuries and ... Medical lifting sling refers to an assistive device that ... slings connect to the lift and hold the patient. ...
(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...
Breaking Medicine Technology: